The impact of polypharmacy on health outcomes in the aged: A retrospective cohort study.

<h4>Objectives</h4>To estimate the prevalence of polypharmacy among community-dwelling adults in the UK and determine its association with mortality, hospitalization, adverse drug reactions and falls at one and five years. To also determine the effect of polypharmacy on the outcomes in d...

Full description

Saved in:
Bibliographic Details
Main Authors: Irene Boateng, Carlos Rodriguez Pascual, Paul Grassby, Zahid Asghar, Kinda Ibrahim
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2025-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0317907
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1825206838089482240
author Irene Boateng
Carlos Rodriguez Pascual
Paul Grassby
Zahid Asghar
Kinda Ibrahim
author_facet Irene Boateng
Carlos Rodriguez Pascual
Paul Grassby
Zahid Asghar
Kinda Ibrahim
author_sort Irene Boateng
collection DOAJ
description <h4>Objectives</h4>To estimate the prevalence of polypharmacy among community-dwelling adults in the UK and determine its association with mortality, hospitalization, adverse drug reactions and falls at one and five years. To also determine the effect of polypharmacy on the outcomes in different patient groups.<h4>Methods</h4>A retrospective cohort study was carried out using 1000 patients aged 75 years and above from the Clinical Practice Research Datalink. The study periods for the one- and five-years analysis were January 2010-December 2010 and January 2010-December 2014 respectively. Sociodemographic and clinical variables were retrieved using medical and product codes. Polypharmacy was defined as the use of five or more medicines. The association between polypharmacy and mortality, falls, adverse drug reactions, or hospitalization was determined using cox regression analysis while confounding for age, sex, Charlson's comorbidity index, potentially inappropriate medicines, hospitalization prior to study, and falls prior to study. Subgroup analysis was used to determine the effect of polypharmacy on the outcomes for different patient groups.<h4>Key findings</h4>977 people were reviewed. 36% were male and the mean age was 83 years. The prevalence of polypharmacy was 47%. Adjusted hazard ratios with their 95% confidence intervals for association between polypharmacy and outcomes at five years were: mortality 1.60 (1.30-2.00), hospitalization 1.49 (1.30-1.70), falls 1.49 (0.90-2.40) and adverse drug reactions 0.97 (0.50-1.80). The results for the one-year analysis were mortality 2.37 (1.40-3.90), hospitalization 2.47 (1.40-4.30), and falls 0.37 (0.03-4.00).<h4>Conclusion</h4>Polypharmacy was found to be a risk factor for mortality and hospitalization. The risk increased with an increase in age, potentially inappropriate medicines and comorbidities.
format Article
id doaj-art-f84d5a783fe0413b94272d4c40832886
institution Kabale University
issn 1932-6203
language English
publishDate 2025-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj-art-f84d5a783fe0413b94272d4c408328862025-02-07T05:30:54ZengPublic Library of Science (PLoS)PLoS ONE1932-62032025-01-01202e031790710.1371/journal.pone.0317907The impact of polypharmacy on health outcomes in the aged: A retrospective cohort study.Irene BoatengCarlos Rodriguez PascualPaul GrassbyZahid AsgharKinda Ibrahim<h4>Objectives</h4>To estimate the prevalence of polypharmacy among community-dwelling adults in the UK and determine its association with mortality, hospitalization, adverse drug reactions and falls at one and five years. To also determine the effect of polypharmacy on the outcomes in different patient groups.<h4>Methods</h4>A retrospective cohort study was carried out using 1000 patients aged 75 years and above from the Clinical Practice Research Datalink. The study periods for the one- and five-years analysis were January 2010-December 2010 and January 2010-December 2014 respectively. Sociodemographic and clinical variables were retrieved using medical and product codes. Polypharmacy was defined as the use of five or more medicines. The association between polypharmacy and mortality, falls, adverse drug reactions, or hospitalization was determined using cox regression analysis while confounding for age, sex, Charlson's comorbidity index, potentially inappropriate medicines, hospitalization prior to study, and falls prior to study. Subgroup analysis was used to determine the effect of polypharmacy on the outcomes for different patient groups.<h4>Key findings</h4>977 people were reviewed. 36% were male and the mean age was 83 years. The prevalence of polypharmacy was 47%. Adjusted hazard ratios with their 95% confidence intervals for association between polypharmacy and outcomes at five years were: mortality 1.60 (1.30-2.00), hospitalization 1.49 (1.30-1.70), falls 1.49 (0.90-2.40) and adverse drug reactions 0.97 (0.50-1.80). The results for the one-year analysis were mortality 2.37 (1.40-3.90), hospitalization 2.47 (1.40-4.30), and falls 0.37 (0.03-4.00).<h4>Conclusion</h4>Polypharmacy was found to be a risk factor for mortality and hospitalization. The risk increased with an increase in age, potentially inappropriate medicines and comorbidities.https://doi.org/10.1371/journal.pone.0317907
spellingShingle Irene Boateng
Carlos Rodriguez Pascual
Paul Grassby
Zahid Asghar
Kinda Ibrahim
The impact of polypharmacy on health outcomes in the aged: A retrospective cohort study.
PLoS ONE
title The impact of polypharmacy on health outcomes in the aged: A retrospective cohort study.
title_full The impact of polypharmacy on health outcomes in the aged: A retrospective cohort study.
title_fullStr The impact of polypharmacy on health outcomes in the aged: A retrospective cohort study.
title_full_unstemmed The impact of polypharmacy on health outcomes in the aged: A retrospective cohort study.
title_short The impact of polypharmacy on health outcomes in the aged: A retrospective cohort study.
title_sort impact of polypharmacy on health outcomes in the aged a retrospective cohort study
url https://doi.org/10.1371/journal.pone.0317907
work_keys_str_mv AT ireneboateng theimpactofpolypharmacyonhealthoutcomesintheagedaretrospectivecohortstudy
AT carlosrodriguezpascual theimpactofpolypharmacyonhealthoutcomesintheagedaretrospectivecohortstudy
AT paulgrassby theimpactofpolypharmacyonhealthoutcomesintheagedaretrospectivecohortstudy
AT zahidasghar theimpactofpolypharmacyonhealthoutcomesintheagedaretrospectivecohortstudy
AT kindaibrahim theimpactofpolypharmacyonhealthoutcomesintheagedaretrospectivecohortstudy
AT ireneboateng impactofpolypharmacyonhealthoutcomesintheagedaretrospectivecohortstudy
AT carlosrodriguezpascual impactofpolypharmacyonhealthoutcomesintheagedaretrospectivecohortstudy
AT paulgrassby impactofpolypharmacyonhealthoutcomesintheagedaretrospectivecohortstudy
AT zahidasghar impactofpolypharmacyonhealthoutcomesintheagedaretrospectivecohortstudy
AT kindaibrahim impactofpolypharmacyonhealthoutcomesintheagedaretrospectivecohortstudy